首页> 外文期刊>Journal of proteome research >Sensitive, Rapid, Robust, and Reproducible Workflow for Host Cell Protein Profiling in Biopharmaceutical Process Development
【24h】

Sensitive, Rapid, Robust, and Reproducible Workflow for Host Cell Protein Profiling in Biopharmaceutical Process Development

机译:用于生物制药过程开发中宿主细胞蛋白质分析的敏感,快速,鲁棒,可重复的工作流程

获取原文
获取原文并翻译 | 示例
           

摘要

There is a growing industry and regulatory need to detect host cell protein (HCP) impurities in the production of protein biopharmaceuticals, as certain HCPs can impact product stability, safety, and efficacy, even at low levels. In some cases, regulatory agencies require the identification and the quantification of HCPs in drug products (DPs) for risk assessment, and this is an active and growing topic of conversation in the industry and amongst regulators. In this study, we developed a sensitive, robust, and reproducible workflow for HCP detection and quantification in a significantly shorter turnaround time than that previously reported using an Evosep ONE LC system coupled to an Orbitrap Fusion Lumos mass spectrometer. Because of its fast turnaround time, this HCP workflow can be integrated into process development for the high-throughput (60 samples analyzed per day) identification of HCPs. The ability to rapidly measure HCPs and follow their clearance throughout the downstream process can be used to pinpoint sources of HCP contamination, which can be used to optimize biopharmaceutical production to minimize HCP levels. Analysis of the NIST monoclonal antibody reference material using the rapid HCP profiling workflow detected the largest number of HCPs reported to date, underscoring an improvement in performance along with an increased throughput. The HCP workflow can be readily implemented and adapted for different purposes to guide biopharmaceutical process development and enable better risk assessment of HCPs in drug substances and DPs.
机译:由于某些HCPS可以影响蛋白质生物制药的生产中,检测宿主细胞蛋白(HCP)杂质的宿主细胞蛋白(HCP)杂质,即使在低水平下也会影响产品稳定性,安全性和疗效。在某些情况下,监管机构需要鉴定和定量用于风险评估的药物产品(DPS)中的HCP,这是行业和监管机构中的谈话的积极和不断增长的话题。在这项研究中,我们开发了一种敏感,鲁棒,可重复的工作流程,用于HCP检测和定量在显着较短的周转时间内,其超短时间比以前使用耦合到围绕围绕围绕融合LUMOS质谱仪的电动仪的时间系统。由于其快速的周转时间,这种HCP工作流程可以集成到过程开发中,以获得HCP的高通量(分析的60个样本)。快速测量HCP并在整个下游过程中遵循它们的清除的能力可用于确定HCP污染的来源,可用于优化生物制药生产以最小化HCP水平。使用快速HCP分析工作流程的NIST单克隆抗体参考资料分析检测到迄今为止报告的最大的HCP数,强调性能提高以及增加的吞吐量。 HCP工作流程可以容易地实施和适应不同的目的,以指导生物制药过程开发,并使药物物质和DPS中HCP的更好风险评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号